The global market for Oligonucleotide Therapeutics Drug was estimated to be worth US$ 325 million in 2023 and is forecast to a readjusted size of US$ 499.3 million by 2030 with a CAGR of 6.0% during the forecast period 2024-2030

Oligonucleotide Therapeutics Drug - Market

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Therapeutics Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oligonucleotide Therapeutics Drug by region & country, by Type, and by Application.

The Oligonucleotide Therapeutics Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Therapeutics Drug.

Market Segmentation

Scope of Oligonucleotide Therapeutics Drug - Market Report

Report Metric	Details
Report Name	Oligonucleotide Therapeutics Drug - Market
Forecasted market size in 2030	US$ 499.3 million
CAGR	6.0%
Forecasted years	2024 - 2030
Segment by Type:	Antisense Oligonucleotide Aptamer Other
Segment by Application	Neuromuscular Diseases ATTR Hepatic VOD Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics, Akcea Therapeutics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Oligonucleotide Therapeutics Drug manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Oligonucleotide Therapeutics Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Oligonucleotide Therapeutics Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Oligonucleotide Therapeutics Drug - Market size in 2030?

Ans: The Oligonucleotide Therapeutics Drug - Market size in 2030 will be US$ 499.3 million.

Who are the main players in the Oligonucleotide Therapeutics Drug - Market report?

Ans: The main players in the Oligonucleotide Therapeutics Drug - Market are Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics, Akcea Therapeutics

What are the Application segmentation covered in the Oligonucleotide Therapeutics Drug - Market report?

Ans: The Applications covered in the Oligonucleotide Therapeutics Drug - Market report are Neuromuscular Diseases, ATTR, Hepatic VOD, Other

What are the Type segmentation covered in the Oligonucleotide Therapeutics Drug - Market report?

Ans: The Types covered in the Oligonucleotide Therapeutics Drug - Market report are Antisense Oligonucleotide, Aptamer, Other

1 Market Overview

1.1 Oligonucleotide Therapeutics Drug Product Introduction

1.2 Global Oligonucleotide Therapeutics Drug Market Size Forecast

1.3 Oligonucleotide Therapeutics Drug Market Trends & Drivers

1.3.1 Oligonucleotide Therapeutics Drug Industry Trends

1.3.2 Oligonucleotide Therapeutics Drug Market Drivers & Opportunity

1.3.3 Oligonucleotide Therapeutics Drug Market Challenges

1.3.4 Oligonucleotide Therapeutics Drug Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Oligonucleotide Therapeutics Drug Players Revenue Ranking (2023)

2.2 Global Oligonucleotide Therapeutics Drug Revenue by Company (2019-2024)

2.3 Key Companies Oligonucleotide Therapeutics Drug Manufacturing Base Distribution and Headquarters

2.4 Key Companies Oligonucleotide Therapeutics Drug Product Offered

2.5 Key Companies Time to Begin Mass Production of Oligonucleotide Therapeutics Drug

2.6 Oligonucleotide Therapeutics Drug Market Competitive Analysis

2.6.1 Oligonucleotide Therapeutics Drug Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Oligonucleotide Therapeutics Drug Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapeutics Drug as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Antisense Oligonucleotide

3.1.2 Aptamer

3.1.3 Other

3.2 Global Oligonucleotide Therapeutics Drug Sales Value by Type

3.2.1 Global Oligonucleotide Therapeutics Drug Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Oligonucleotide Therapeutics Drug Sales Value, by Type (2019-2030)

3.2.3 Global Oligonucleotide Therapeutics Drug Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Neuromuscular Diseases

4.1.2 ATTR

4.1.3 Hepatic VOD

4.1.4 Other

4.2 Global Oligonucleotide Therapeutics Drug Sales Value by Application

4.2.1 Global Oligonucleotide Therapeutics Drug Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Oligonucleotide Therapeutics Drug Sales Value, by Application (2019-2030)

4.2.3 Global Oligonucleotide Therapeutics Drug Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Oligonucleotide Therapeutics Drug Sales Value by Region

5.1.1 Global Oligonucleotide Therapeutics Drug Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Oligonucleotide Therapeutics Drug Sales Value by Region (2019-2024)

5.1.3 Global Oligonucleotide Therapeutics Drug Sales Value by Region (2025-2030)

5.1.4 Global Oligonucleotide Therapeutics Drug Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Oligonucleotide Therapeutics Drug Sales Value, 2019-2030

5.2.2 North America Oligonucleotide Therapeutics Drug Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Oligonucleotide Therapeutics Drug Sales Value, 2019-2030

5.3.2 Europe Oligonucleotide Therapeutics Drug Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Oligonucleotide Therapeutics Drug Sales Value, 2019-2030

5.4.2 Asia Pacific Oligonucleotide Therapeutics Drug Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Oligonucleotide Therapeutics Drug Sales Value, 2019-2030

5.5.2 South America Oligonucleotide Therapeutics Drug Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Oligonucleotide Therapeutics Drug Sales Value, 2019-2030

5.6.2 Middle East & Africa Oligonucleotide Therapeutics Drug Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Oligonucleotide Therapeutics Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Oligonucleotide Therapeutics Drug Sales Value

6.3 United States

6.3.1 United States Oligonucleotide Therapeutics Drug Sales Value, 2019-2030

6.3.2 United States Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Oligonucleotide Therapeutics Drug Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Oligonucleotide Therapeutics Drug Sales Value, 2019-2030

6.4.2 Europe Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Oligonucleotide Therapeutics Drug Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Oligonucleotide Therapeutics Drug Sales Value, 2019-2030

6.5.2 China Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

6.5.3 China Oligonucleotide Therapeutics Drug Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Oligonucleotide Therapeutics Drug Sales Value, 2019-2030

6.6.2 Japan Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Oligonucleotide Therapeutics Drug Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Oligonucleotide Therapeutics Drug Sales Value, 2019-2030

6.7.2 South Korea Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Oligonucleotide Therapeutics Drug Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Oligonucleotide Therapeutics Drug Sales Value, 2019-2030

6.8.2 Southeast Asia Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Oligonucleotide Therapeutics Drug Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Oligonucleotide Therapeutics Drug Sales Value, 2019-2030

6.9.2 India Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

6.9.3 India Oligonucleotide Therapeutics Drug Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Biogen

7.1.1 Biogen Profile

7.1.2 Biogen Main Business

7.1.3 Biogen Oligonucleotide Therapeutics Drug Products, Services and Solutions

7.1.4 Biogen Oligonucleotide Therapeutics Drug Revenue (US$ Million) & (2019-2024)

7.1.5 Biogen Recent Developments

7.2 Sarepta Therapeutics

7.2.1 Sarepta Therapeutics Profile

7.2.2 Sarepta Therapeutics Main Business

7.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Drug Products, Services and Solutions

7.2.4 Sarepta Therapeutics Oligonucleotide Therapeutics Drug Revenue (US$ Million) & (2019-2024)

7.2.5 Sarepta Therapeutics Recent Developments

7.3 Jazz Pharmaceuticals

7.3.1 Jazz Pharmaceuticals Profile

7.3.2 Jazz Pharmaceuticals Main Business

7.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Drug Products, Services and Solutions

7.3.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Drug Revenue (US$ Million) & (2019-2024)

7.3.5 Bausch & Lomb Recent Developments

7.4 Bausch & Lomb

7.4.1 Bausch & Lomb Profile

7.4.2 Bausch & Lomb Main Business

7.4.3 Bausch & Lomb Oligonucleotide Therapeutics Drug Products, Services and Solutions

7.4.4 Bausch & Lomb Oligonucleotide Therapeutics Drug Revenue (US$ Million) & (2019-2024)

7.4.5 Bausch & Lomb Recent Developments

7.5 Alnylam Pharmaceuticals

7.5.1 Alnylam Pharmaceuticals Profile

7.5.2 Alnylam Pharmaceuticals Main Business

7.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Drug Products, Services and Solutions

7.5.4 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Drug Revenue (US$ Million) & (2019-2024)

7.5.5 Alnylam Pharmaceuticals Recent Developments

7.6 Dynavax Technologies

7.6.1 Dynavax Technologies Profile

7.6.2 Dynavax Technologies Main Business

7.6.3 Dynavax Technologies Oligonucleotide Therapeutics Drug Products, Services and Solutions

7.6.4 Dynavax Technologies Oligonucleotide Therapeutics Drug Revenue (US$ Million) & (2019-2024)

7.6.5 Dynavax Technologies Recent Developments

7.7 Kastle therapeutics

7.7.1 Kastle therapeutics Profile

7.7.2 Kastle therapeutics Main Business

7.7.3 Kastle therapeutics Oligonucleotide Therapeutics Drug Products, Services and Solutions

7.7.4 Kastle therapeutics Oligonucleotide Therapeutics Drug Revenue (US$ Million) & (2019-2024)

7.7.5 Kastle therapeutics Recent Developments

7.8 Akcea Therapeutics

7.8.1 Akcea Therapeutics Profile

7.8.2 Akcea Therapeutics Main Business

7.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Drug Products, Services and Solutions

7.8.4 Akcea Therapeutics Oligonucleotide Therapeutics Drug Revenue (US$ Million) & (2019-2024)

7.8.5 Akcea Therapeutics Recent Developments

8 Industry Chain Analysis

8.1 Oligonucleotide Therapeutics Drug Industrial Chain

8.2 Oligonucleotide Therapeutics Drug Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Oligonucleotide Therapeutics Drug Sales Model

8.5.2 Sales Channel

8.5.3 Oligonucleotide Therapeutics Drug Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Alnylam Pharmaceuticals

Dynavax Technologies

Kastle therapeutics

Akcea Therapeutics

List of Tables

Table 1. Oligonucleotide Therapeutics Drug Market Trends

Table 2. Oligonucleotide Therapeutics Drug Market Drivers & Opportunity

Table 3. Oligonucleotide Therapeutics Drug Market Challenges

Table 4. Oligonucleotide Therapeutics Drug Market Restraints

Table 5. Global Oligonucleotide Therapeutics Drug Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Oligonucleotide Therapeutics Drug Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Oligonucleotide Therapeutics Drug Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Oligonucleotide Therapeutics Drug Product Type

Table 9. Key Companies Time to Begin Mass Production of Oligonucleotide Therapeutics Drug

Table 10. Global Oligonucleotide Therapeutics Drug Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapeutics Drug as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Oligonucleotide Therapeutics Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Oligonucleotide Therapeutics Drug Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Oligonucleotide Therapeutics Drug Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Oligonucleotide Therapeutics Drug Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Oligonucleotide Therapeutics Drug Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Oligonucleotide Therapeutics Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Oligonucleotide Therapeutics Drug Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Oligonucleotide Therapeutics Drug Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Oligonucleotide Therapeutics Drug Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Oligonucleotide Therapeutics Drug Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Oligonucleotide Therapeutics Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Oligonucleotide Therapeutics Drug Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Oligonucleotide Therapeutics Drug Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Oligonucleotide Therapeutics Drug Sales Value by Region (2019-2024) & (%)

Table 27. Global Oligonucleotide Therapeutics Drug Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Oligonucleotide Therapeutics Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Oligonucleotide Therapeutics Drug Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Oligonucleotide Therapeutics Drug Sales Value, (2025-2030) & (US$ Million)

Table 31. Biogen Basic Information List

Table 32. Biogen Description and Business Overview

Table 33. Biogen Oligonucleotide Therapeutics Drug Products, Services and Solutions

Table 34. Revenue (US$ Million) in Oligonucleotide Therapeutics Drug Business of Biogen (2019-2024)

Table 35. Biogen Recent Developments

Table 36. Sarepta Therapeutics Basic Information List

Table 37. Sarepta Therapeutics Description and Business Overview

Table 38. Sarepta Therapeutics Oligonucleotide Therapeutics Drug Products, Services and Solutions

Table 39. Revenue (US$ Million) in Oligonucleotide Therapeutics Drug Business of Sarepta Therapeutics (2019-2024)

Table 40. Sarepta Therapeutics Recent Developments

Table 41. Jazz Pharmaceuticals Basic Information List

Table 42. Jazz Pharmaceuticals Description and Business Overview

Table 43. Jazz Pharmaceuticals Oligonucleotide Therapeutics Drug Products, Services and Solutions

Table 44. Revenue (US$ Million) in Oligonucleotide Therapeutics Drug Business of Jazz Pharmaceuticals (2019-2024)

Table 45. Jazz Pharmaceuticals Recent Developments

Table 46. Bausch & Lomb Basic Information List

Table 47. Bausch & Lomb Description and Business Overview

Table 48. Bausch & Lomb Oligonucleotide Therapeutics Drug Products, Services and Solutions

Table 49. Revenue (US$ Million) in Oligonucleotide Therapeutics Drug Business of Bausch & Lomb (2019-2024)

Table 50. Bausch & Lomb Recent Developments

Table 51. Alnylam Pharmaceuticals Basic Information List

Table 52. Alnylam Pharmaceuticals Description and Business Overview

Table 53. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Drug Products, Services and Solutions

Table 54. Revenue (US$ Million) in Oligonucleotide Therapeutics Drug Business of Alnylam Pharmaceuticals (2019-2024)

Table 55. Alnylam Pharmaceuticals Recent Developments

Table 56. Dynavax Technologies Basic Information List

Table 57. Dynavax Technologies Description and Business Overview

Table 58. Dynavax Technologies Oligonucleotide Therapeutics Drug Products, Services and Solutions

Table 59. Revenue (US$ Million) in Oligonucleotide Therapeutics Drug Business of Dynavax Technologies (2019-2024)

Table 60. Dynavax Technologies Recent Developments

Table 61. Kastle therapeutics Basic Information List

Table 62. Kastle therapeutics Description and Business Overview

Table 63. Kastle therapeutics Oligonucleotide Therapeutics Drug Products, Services and Solutions

Table 64. Revenue (US$ Million) in Oligonucleotide Therapeutics Drug Business of Kastle therapeutics (2019-2024)

Table 65. Kastle therapeutics Recent Developments

Table 66. Akcea Therapeutics Basic Information List

Table 67. Akcea Therapeutics Description and Business Overview

Table 68. Akcea Therapeutics Oligonucleotide Therapeutics Drug Products, Services and Solutions

Table 69. Revenue (US$ Million) in Oligonucleotide Therapeutics Drug Business of Akcea Therapeutics (2019-2024)

Table 70. Akcea Therapeutics Recent Developments

Table 71. Key Raw Materials Lists

Table 72. Raw Materials Key Suppliers Lists

Table 73. Oligonucleotide Therapeutics Drug Downstream Customers

Table 74. Oligonucleotide Therapeutics Drug Distributors List

Table 75. Research Programs/Design for This Report

Table 76. Key Data Information from Secondary Sources

Table 77. Key Data Information from Primary Sources

Table 78. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Oligonucleotide Therapeutics Drug Product Picture

Figure 2. Global Oligonucleotide Therapeutics Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Oligonucleotide Therapeutics Drug Sales Value (2019-2030) & (US$ Million)

Figure 4. Oligonucleotide Therapeutics Drug Report Years Considered

Figure 5. Global Oligonucleotide Therapeutics Drug Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Oligonucleotide Therapeutics Drug Revenue in 2023

Figure 7. Oligonucleotide Therapeutics Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Antisense Oligonucleotide Picture

Figure 9. Aptamer Picture

Figure 10. Other Picture

Figure 11. Global Oligonucleotide Therapeutics Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 12. Global Oligonucleotide Therapeutics Drug Sales Value Market Share by Type, 2023 & 2030

Figure 13. Product Picture of Neuromuscular Diseases

Figure 14. Product Picture of ATTR

Figure 15. Product Picture of Hepatic VOD

Figure 16. Product Picture of Other

Figure 17. Global Oligonucleotide Therapeutics Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Oligonucleotide Therapeutics Drug Sales Value Market Share by Application, 2023 & 2030

Figure 19. North America Oligonucleotide Therapeutics Drug Sales Value (2019-2030) & (US$ Million)

Figure 20. North America Oligonucleotide Therapeutics Drug Sales Value by Country (%), 2023 VS 2030

Figure 21. Europe Oligonucleotide Therapeutics Drug Sales Value (2019-2030) & (US$ Million)

Figure 22. Europe Oligonucleotide Therapeutics Drug Sales Value by Country (%), 2023 VS 2030

Figure 23. Asia Pacific Oligonucleotide Therapeutics Drug Sales Value (2019-2030) & (US$ Million)

Figure 24. Asia Pacific Oligonucleotide Therapeutics Drug Sales Value by Country (%), 2023 VS 2030

Figure 25. South America Oligonucleotide Therapeutics Drug Sales Value (2019-2030) & (US$ Million)

Figure 26. South America Oligonucleotide Therapeutics Drug Sales Value by Country (%), 2023 VS 2030

Figure 27. Middle East & Africa Oligonucleotide Therapeutics Drug Sales Value (2019-2030) & (US$ Million)

Figure 28. Middle East & Africa Oligonucleotide Therapeutics Drug Sales Value by Country (%), 2023 VS 2030

Figure 29. Key Countries/Regions Oligonucleotide Therapeutics Drug Sales Value (%), (2019-2030)

Figure 30. United States Oligonucleotide Therapeutics Drug Sales Value, (2019-2030) & (US$ Million)

Figure 31. United States Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

Figure 32. United States Oligonucleotide Therapeutics Drug Sales Value by Application (%), 2023 VS 2030

Figure 33. Europe Oligonucleotide Therapeutics Drug Sales Value, (2019-2030) & (US$ Million)

Figure 34. Europe Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

Figure 35. Europe Oligonucleotide Therapeutics Drug Sales Value by Application (%), 2023 VS 2030

Figure 36. China Oligonucleotide Therapeutics Drug Sales Value, (2019-2030) & (US$ Million)

Figure 37. China Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

Figure 38. China Oligonucleotide Therapeutics Drug Sales Value by Application (%), 2023 VS 2030

Figure 39. Japan Oligonucleotide Therapeutics Drug Sales Value, (2019-2030) & (US$ Million)

Figure 40. Japan Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

Figure 41. Japan Oligonucleotide Therapeutics Drug Sales Value by Application (%), 2023 VS 2030

Figure 42. South Korea Oligonucleotide Therapeutics Drug Sales Value, (2019-2030) & (US$ Million)

Figure 43. South Korea Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

Figure 44. South Korea Oligonucleotide Therapeutics Drug Sales Value by Application (%), 2023 VS 2030

Figure 45. Southeast Asia Oligonucleotide Therapeutics Drug Sales Value, (2019-2030) & (US$ Million)

Figure 46. Southeast Asia Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

Figure 47. Southeast Asia Oligonucleotide Therapeutics Drug Sales Value by Application (%), 2023 VS 2030

Figure 48. India Oligonucleotide Therapeutics Drug Sales Value, (2019-2030) & (US$ Million)

Figure 49. India Oligonucleotide Therapeutics Drug Sales Value by Type (%), 2023 VS 2030

Figure 50. India Oligonucleotide Therapeutics Drug Sales Value by Application (%), 2023 VS 2030

Figure 51. Oligonucleotide Therapeutics Drug Industrial Chain

Figure 52. Oligonucleotide Therapeutics Drug Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-38B2538

Sat Oct 12 00:00:00 UTC 2024

Add to Cart

Rheumatoid Arthritis Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-5A13262

Sat Oct 12 00:00:00 UTC 2024

Add to Cart

Psoriasis Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-28R2574

Sat Oct 12 00:00:00 UTC 2024

Add to Cart

Global Pharmaceutical Rubber Stopper Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-15W7068

Sat Oct 12 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Oligonucleotide Therapeutics Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: September 2024

Report Code: QYRE-Auto-16M13745

Oligonucleotide Therapeutics Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

FEATURED COMPANIES

Oligonucleotide Therapeutics Drug - Market Size

Oligonucleotide Therapeutics Drug - Market

Report Scope

Scope of Oligonucleotide Therapeutics Drug - Market Report

Chapter Outline

FAQ for this report

What is the Oligonucleotide Therapeutics Drug - Market size in 2030?

Who are the main players in the Oligonucleotide Therapeutics Drug - Market report?

What are the Application segmentation covered in the Oligonucleotide Therapeutics Drug - Market report?

What are the Type segmentation covered in the Oligonucleotide Therapeutics Drug - Market report?

FEATURED COMPANIES

RELATED REPORTS